Zealand Pharma A/S's latest marketcap:
As of 04/30/2026, Zealand Pharma A/S's market capitalization has reached $3.33 B. According to our data, Zealand Pharma A/S is the 5104th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 3.33 B |
| Revenue (ttm) | 1.44 B |
| Net Income (ttm) | 1.01 B |
| Shares Out | 70.62 M |
| EPS (ttm) | 14.12 |
| Forward PE | 16.62 |
| Ex-Dividend Date | n/a |
| Earnings Date | 05/07/2026 |
Zealand Pharma A/S's yearly market capitalization.
| Date | Market Cap(kr) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 06/02/2026 | kr21.4 B | $3.38 B | -34.85% | n/a |
| 12/30/2025 | kr32.85 B | $5.11 B | -35.01% | 3168 |
| 12/30/2024 | kr50.55 B | $6.99 B | 132.03% | 2307 |
| 12/29/2023 | kr21.79 B | $3.22 B | 110.16% | 4056 |
| 12/30/2022 | kr10.37 B | $1.49 B | 65.31% | 6485 |
| 12/30/2021 | kr6.27 B | $958.4 M | -28.46% | 9570 |
| 12/30/2020 | kr8.77 B | $1.43 B | 3.46% | 6475 |
| 12/30/2019 | kr8.47 B | $1.27 B | 234.66% | 5952 |
| 12/28/2018 | kr2.53 B | $387.58 M | -1.34% | 10417 |
| 12/29/2017 | kr2.57 B | $411.57 M | -5.81% | 11341 |
Company Profile
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company specializing in the discovery, development, and commercialization of peptide-based medicines. Headquartered in Søborg, Denmark, the company operates in Denmark and the United States.
Key Focus Areas
The company's portfolio targets:
- Gastrointestinal diseases
- Metabolic disorders
- Specialty disease areas with unmet medical needs
Products and Pipeline
Zealand Pharma offers innovative treatments, including:
- Zegalogue: A single-use syringe or autoinjector for severe hypoglycemia treatment.
- Dasiglucagon bi-hormone artificial pancreas systems: Combines insulin and dasiglucagon for advanced diabetes management.
The company's pipeline features promising candidates such as:
- Dasiglucagon: Under development for congenital hyperinsulinism.
- Glepaglutide: A long-acting GLP-2 analog in Phase III trials for short bowel syndrome.
Company Background
Founded in 1997, Zealand Pharma A/S has established itself as a leader in peptide-based therapeutics, addressing critical healthcare challenges worldwide.
Frequently Asked Questions
-
What is Zealand Pharma A/S's (CPH-ZEAL) current market cap?As of 04/30/2026, Zealand Pharma A/S (including the parent company, if applicable) has an estimated market capitalization of $3.33 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Zealand Pharma A/S (CPH-ZEAL) rank globally by market cap?Zealand Pharma A/S global market capitalization ranking is approximately 5104 as of 04/30/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.